drugset

drugset / Trial / NCT06151587

A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children

NCT06151587 ↗

Phase 3 Recruiting 735 enrolled Qilu Pharmaceutical Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

Efficacy and Safety Study of QLM3004 in Myopic Children

Timeline

Start: 2023-08-20
Primary completion: 2026-06
Completion: 2027-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	QLM3004	Unknown	—	Other

Indications